Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1642413rdf:typepubmed:Citationlld:pubmed
pubmed-article:1642413lifeskim:mentionsumls-concept:C0025202lld:lifeskim
pubmed-article:1642413lifeskim:mentionsumls-concept:C0460004lld:lifeskim
pubmed-article:1642413lifeskim:mentionsumls-concept:C0302350lld:lifeskim
pubmed-article:1642413lifeskim:mentionsumls-concept:C0220901lld:lifeskim
pubmed-article:1642413pubmed:issue1lld:pubmed
pubmed-article:1642413pubmed:dateCreated1992-8-28lld:pubmed
pubmed-article:1642413pubmed:abstractTextTherapeutic considerations are discussed based on recurrence and survival statistics of 900 patients treated at Duke University Medical Center (Durham, NC). Approximately one-third of all patients developed recurrence. Factors affecting recurrence include tumor thickness, presence of positive regional nodes at diagnosis, and advanced Clark level. Patients with more than one adverse index had even higher rates of recurrence than with one alone. The 5-year survival of all patients after recurrence was 32%. Therapeutic decisions should include considerations that relate to patients' recurrence patterns and survival curves.lld:pubmed
pubmed-article:1642413pubmed:languageenglld:pubmed
pubmed-article:1642413pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1642413pubmed:citationSubsetIMlld:pubmed
pubmed-article:1642413pubmed:statusMEDLINElld:pubmed
pubmed-article:1642413pubmed:monthJanlld:pubmed
pubmed-article:1642413pubmed:issn0148-7043lld:pubmed
pubmed-article:1642413pubmed:authorpubmed-author:GeorgeS LSLlld:pubmed
pubmed-article:1642413pubmed:authorpubmed-author:SeiglerH FHFlld:pubmed
pubmed-article:1642413pubmed:authorpubmed-author:FisherS RSRlld:pubmed
pubmed-article:1642413pubmed:issnTypePrintlld:pubmed
pubmed-article:1642413pubmed:volume28lld:pubmed
pubmed-article:1642413pubmed:ownerNLMlld:pubmed
pubmed-article:1642413pubmed:authorsCompleteYlld:pubmed
pubmed-article:1642413pubmed:pagination78-80lld:pubmed
pubmed-article:1642413pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:1642413pubmed:meshHeadingpubmed-meshheading:1642413-...lld:pubmed
pubmed-article:1642413pubmed:meshHeadingpubmed-meshheading:1642413-...lld:pubmed
pubmed-article:1642413pubmed:meshHeadingpubmed-meshheading:1642413-...lld:pubmed
pubmed-article:1642413pubmed:meshHeadingpubmed-meshheading:1642413-...lld:pubmed
pubmed-article:1642413pubmed:meshHeadingpubmed-meshheading:1642413-...lld:pubmed
pubmed-article:1642413pubmed:meshHeadingpubmed-meshheading:1642413-...lld:pubmed
pubmed-article:1642413pubmed:meshHeadingpubmed-meshheading:1642413-...lld:pubmed
pubmed-article:1642413pubmed:meshHeadingpubmed-meshheading:1642413-...lld:pubmed
pubmed-article:1642413pubmed:meshHeadingpubmed-meshheading:1642413-...lld:pubmed
pubmed-article:1642413pubmed:meshHeadingpubmed-meshheading:1642413-...lld:pubmed
pubmed-article:1642413pubmed:meshHeadingpubmed-meshheading:1642413-...lld:pubmed
pubmed-article:1642413pubmed:year1992lld:pubmed
pubmed-article:1642413pubmed:articleTitleTherapeutic and prognostic considerations of head and neck melanoma.lld:pubmed
pubmed-article:1642413pubmed:affiliationDuke University Medical Center, Durham, NC 27710.lld:pubmed
pubmed-article:1642413pubmed:publicationTypeJournal Articlelld:pubmed